Outcomes of acute myocardial infarction patients with supranormal versus normal or reduced left ventricular ejection fraction

This study utilized a large Korean nationwide cohort comprising 27,903 patients diagnosed with acute myocardial infarction (AMI) between November 2011 and June 2020. The population was stratified into four distinct groups based on left ventricular ejection fraction (LVEF): supranormal (≥65%), normal (50–64%), mid-range (40–49%), and reduced. The primary comparator group consisted of AMI patients with normal, mid-range, or reduced LVEF values.

The provided evidence explicitly states that main results were not reported within the available data. Furthermore, specific details regarding the primary outcome, secondary outcomes, follow-up duration, and adverse event profiles were not included in the input. Therefore, no quantitative data on mortality, reinfarction, or other clinical endpoints can be presented.

Safety and tolerability data, including adverse events, serious adverse events, discontinuations, and general tolerability, were not reported. The study is characterized as real-world evidence, yet the input notes that evidence on outcomes for patients with AMI and supranormal LVEF is currently lacking. This gap in the literature limits the ability to confirm whether supranormal LVEF confers a distinct prognostic advantage or disadvantage in this specific cohort.

Due to the absence of reported main results and the acknowledged lack of existing real-world evidence for this specific subgroup, the practice relevance remains undefined. Clinicians should interpret these findings with caution, recognizing that the data does not currently support specific recommendations for patients with supranormal LVEF following AMI.